About us
- >
- About us >
- Information >
- Announcement
2023-02-10
Patent for "Compound Activating AMPK and Uses Thereof" aimed at treating inflammatory diseases has been approved in Canada.
Patent application for "Compound for Activating AMPK and Uses Thereof" aimed at treating ankylosing spondylitis, arthritis, asthma, atherosclerosis, fibromyalgia, and systemic lupus erythematosus has been approved by Innovation, Science, and Economic Development Canada (ISED). The patent application number is 3112089.